Table 1 Results of patient testing before and after IVIg administration, discrepant results noted in bold
From: Clinical false positives resulting from recent intravenous immunoglobulin therapy: case report
Investigation | Reference intervals | Pre-IVIg | Â | Post IVIg | Â |
|---|---|---|---|---|---|
| Â | (units) | Interpretation | Value | Interpretation | Value |
Total IgA | 0.4–3.5 (g/L) | Normal | 1.16 | Normal | 1.1 |
Total IgG | 6.5–16.0 (g/L) | Normal | 10.01 | High | 36.93 |
Total IgM | 0.5–3.0 (g/L) | Normal | 0.63 | Normal | 0.59 |
CMV IgG | < 0.5 (U/mL) | Negative | < 0.3 | Positive | 467 |
Hepatitis A total antibody | < 20.0 (IU/L) | Negative | 8.0 | Positive | > 60 |
Hepatitis A IgM antibody | < 1.0 (COI) | Negative | < 0.3 | Negative | < 0.3 |
Hepatitis B surface IgG antibody | < 10.0 (IU/L) a | Positive | > 1000 | Positive | > 1000 |
Hepatitis B core IgM antibody | < 1.0 (COI) | Negative | 0.1 | Negative | 0.1 |
Hepatitis B core total antibodies b | > 1.0 (COI) | Negative | 2.3 | Positive | < 0.8 |
Hepatitis B surface antigen | < 0.9 (COI) | Negative | 0.3 | Negative | 0.3 |
Hepatitis C antibody | < 0.9 (COI) | Negative | 0 | Negative | 0.1 |